NCT03649620

A 12-week, Randomized, Double-blind, Placebo-controlled Human Trial to Evaluate the Efficacy and Safety of Unripe Bokbunja Extract on Improvement of Blood Cholesterol

Completed NA Last updated 24 August 2018

What this trial tests

NA trial testing unripe Bokbunja Extract in Blood Cholesterol in 80 participants. Completed in 1 February 2018.

Timeline

1 December 2016

Primary endpoint
1 May 2017

1 February 2018

Quick facts

Lead sponsor	Yonsei University
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	prevention
Enrollment	80
Start date	1 December 2016
Primary completion	1 May 2017
Estimated completion	1 February 2018

Drugs / interventions tested

• unripe Bokbunja Extract
• Placebo

Conditions studied

• Blood Cholesterol — all drugs for Blood Cholesterol →

Sponsor

Yonsei University

Who can join

Adults 20 to 65, any sex, with Blood Cholesterol. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Changes of Total cholesterol
  Time frame: 12 weeks
  Changes of total cholesterol were assessed before and after the intervention

Sponsor's own description

This study was conducted to investigate the effects of daily supplementation of unripe Bokbunja extract on improvement of blood cholesterol.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. The cholesterol-lowering effect of unripe Rubus coreanus is associated with decreased oxidized LDL and apolipoprotein B levels in subjects with borderline-high cholesterol levels: a randomized controlled trial.
   Cho JM, Chae J, Jeong SR, Moon MJ, et al · · 2020 · cited 10× · PMID 32646501 · DOI 10.1186/s12944-020-01338-z